Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1992-09-29
1994-11-22
Hook, Gregory
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514267, A61K 3152, A61K 31505
Patent
active
053669770
ABSTRACT:
A method of treating cells having a reduced apical Cl.sup.- conductance, such as that characteristic of cystic fibrosis cells, by contacting cells having a reduced apical Cl.sup.- conductance with a therapeutically effective quantity of a compound that antagonizes the A.sub.1 -adenosine cell receptor and does not antagonize the A.sub.2 -adenosine cell receptor. Suitable compounds include 8-cyclopentyl-1,3-dipropylxanthine (CPX), xanthine amino congener (XAC), and therapeutically effective derivatives thereof.
REFERENCES:
patent: 4769377 (1988-09-01), Snyder
patent: 4772607 (1988-09-01), Badger
patent: 4968672 (1990-11-01), Jacobson
patent: 5032593 (1991-07-01), Rzeszotarski
Beach et al Chem Abstr. 118(3): 19932 of Am. J. Physiol. 263(3,Pt 2) F482-487 (Sep. 1992).
Alzheimer et al, Neuroscience Let. 99: 107-112 (1989).
Eidelman et al "A.sub.1 adenosine-receptor antagonists" Proc. Natl. Acad. Sci. 89: 5562-5566 Jun. 1992.
Merck Manual, 14th ed., pp. 634-639, 1982.
Arispe et al., "Intrinsic anion channel activity of the recombinant first nucleotide binding fold domain of the cystic fibrosis transmembrane regulator protein," Proc. Natl. Acad. Sci. USA, 89: 1539-1543. Mar 1992.
Barrett et al., "Differing effects of apical and basolateral adenosine on colonic epithelial cell line T.sub.84, " Am. J. Physiol. 256 (Cell Physiol. 25): C197-C203. 1989.
Baumgold et al., "Penetration of Adenosine Antagonists Into Mouse Brain As Determined By Ex Vivo Binding," Biochemical Pharmacology, 43(4): 889-894. 1992.
Behnke et al., "Differential Antagonism by 1,3-Dipropylxanthine-8-cyclopentylxanthine and 9-Chloro-2-(2-Furanyl)-5,6-Dihydro-2,4-Triazolo(1,5-c)quinazolin-5-imine . . . in Cardiomyocytes," Journal of Pharmacology and Experimental Therapeutics, 254(3): 1017-1023. 1990.
Bohm, et al., "Characterization of A.sub.1 Adenosine Receptors in Atrial and Ventricular Myocardium From Diseased Human Hearts," Circulation Research, 65(5): 1201-1211. Nov. 1989.
Brackett et al., "Activities of Caffeine, Theophylline, and Enprofylline Analogs As Tracheal Relaxants," Biochemical Pharmacology, 39(12): 1897-1904. 1990.
Bruns et al., "Binding of the A.sub.1 -selective adenosine antagonist 8-cyclopentyl-1,3-dipropylxanthine to rat brain membranes," Naunyn-Schmiedberg's Arch. Pharmacol., 335: 59-63. 1987.
Drumm et al., "Chloride Conductance Expressed by .DELTA.F508 and Other Mutant CFTRs in Xeinopus Oocytes," Science, 254: 1797-1799. Dec. 20, 1991.
Garritsen et al., "Chemical Modification of Adenosine A.sub.1 Receptors," Biochemical Pharmacology, 40(4): 835-842. 1990.
Jacobson et al., "8-Substituted Xanthines as Antagonists at A.sub.1 - and A.sub.2 - Adenosine Receptors," Biochemical Pharmacology, 37(19): 3653-3661. 1988.
Jacobson et al., "Adenosine (P.sub.1) and ATP (P.sub.2) Receptors,"Comprehensive Medicinal Chemistry, 3(Membranes and Receptors): 601-642. 1990.
Jacobson et al., "Novel Therapeutics Acting Via Purine Receptors," Biochemical Pharmacology, 41(10): 1399-1410. 1991.
Ji et al., "Characterization of Human Striatal A.sub.2 -Adenosine Receptors Using Radioligand Binding and Photoaffinity Labelling," Journal of Receptor Research, 12(2): 149-169. 1992.
Kellett et al., "Amelioration of glycerol-induced acute renal failure in the rat with 8-cyclopentyl-1,3-dipropylxanthine," Br. J. Pharmacol., 98: 1066-1074. 1989.
Kelley et al., "Endogenous Adenosine is an Autacoid Feedback Inhibitor of Chloride Transport in the Shark Rectal Gland," J. Clin. Invest., 88: 1933-1939. Dec. 1991.
Knowles et al., "A Pilot Study of Aerosolized Amiloride For The Treatment of Lung Disease In Cystic Fibrosis," The New England Journal of Medicine, 322(17): 1189-1194. Apr. 26, 1990.
Knowles et al., "Activation By Extracellular Nucleotides of Chloride Secretion In The Airway Epithelia of Patients With Cystic Fibrosis," The New England Journal of Medicine, 325(8): 533-538. Aug. 22, 1991.
Schepp et al., "Dual modulation by adenosine of gastrin release from canine g-cells in primary culture," Am. J. Physiol. 259 (Gastrointest. Liver Physiol. 22): G556-G563. 1990.
Snyder et al., Proc. Natl. Acad. Sci. USA, 78(5): 3260-3264. May 1981.
von der Leyen et al., "Effects of 1,3-dipropyl-8-cyclopentylxanthine (DPCPX), a highly selective andenosine receptor atangonist, on force of contraction in guinea-pig atrial and ventricular cardiac preparations," Nauyn-Schmiedeberg's Arch. Pharmacol., 340: 204-209. 1989.
Jacobson Kenneth A.
Pollard Harvey B.
van Galen Philip J. M.
Hook Gregory
The United States of America as represented by the Department o
LandOfFree
Method of treating cystic fibrosis using 8-cyclopentyl-1,3-dipro does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of treating cystic fibrosis using 8-cyclopentyl-1,3-dipro, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of treating cystic fibrosis using 8-cyclopentyl-1,3-dipro will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1991588